The study tested whether PF’3944 could maintain efficacy when switching from weekly to monthly injections and remain safe and well-tolerated
The partnership builds on a prior collaboration between Nimbus and Lilly targeting AMPK in cardiometabolic diseases
The decision secures legal protection in China for semaglutide, the blockbuster drug underpinning Novo Nordisk’s diabetes and obesity treatments
Enabling a new era in minimally invasive obesity treatment across Europe
Agreements mark a major victory in the President’s long-term pledge to lower prescription drug costs for Americans
Poviztra is a second brand of Wegovy
The discussions come as part of the administration’s broader efforts to drive down drug prices and increase patient access to essential therapies
Wegovy achieved significant weight loss with one in three study participants losing 20% or more body weight
Subscribe To Our Newsletter & Stay Updated
